Demo Sign up Log In

Lineage Cell Therapeutics, Inc. Common Stock (LCTX)

Cost of Revenue

$446.00K

TTM · Period ending: Jun 30, 2026 · USD

LCTX Cost of Revenue

Latest reported$446.00Kperiod endingJun 30, 2026

Latest reported$446.00Kperiod endingJun 30, 2026

LCTX TTM Cost of Revenue ($600.00K → $446.00K)

TTM cost of revenue

High-resolution chart · PNG

LCTX cost of revenue history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

Lineage Cell Therapeutics, Inc. Common Stock Cost of Revenue — Trailing twelve months (TTM) (USD)
Period ending	Cost of Revenue (USD)
Jun 30, 2001	-38,675
Mar 31, 2001	-57,204
Dec 31, 2000	-75,458
Sep 30, 2000	-56,130
Jun 30, 2000	-36,783
Mar 31, 2000	-18,254
Dec 31, 1999	0
Sep 30, 1999	0
Jun 30, 1999	0
Mar 31, 1999	0
Sep 30, 1998	0
Jun 30, 1998	0
Mar 31, 1998	0
Dec 31, 1997	0
Sep 30, 1997	0
Jun 30, 1997	0
Mar 31, 1997	0
Dec 31, 1996	0
Sep 30, 1996	0
Jun 30, 1996	200,000
Mar 31, 1996	200,000
Dec 31, 1995	200,000
Sep 30, 1995	200,000
Jun 30, 1995	0
Mar 31, 1995	0
Dec 31, 1994	0
Sep 30, 1994	200,000
Jun 30, 1994	400,000
Mar 31, 1994	600,000
Dec 31, 1993	700,000
Sep 30, 1993	700,000
Jun 30, 1993	600,000
Mar 31, 1993	600,000
Dec 31, 1992	600,000

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.